Galectin Therapeutics Inc (GALT)
3.46
-0.04
(-1.14%)
USD |
NASDAQ |
Apr 26, 16:00
3.46
0.00 (0.00%)
After-Hours: 19:12
Galectin Therapeutics Research and Development Expense (Quarterly): 8.228M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 8.228M |
| September 30, 2023 | 7.732M |
| June 30, 2023 | 7.371M |
| March 31, 2023 | 8.799M |
| December 31, 2022 | 9.007M |
| September 30, 2022 | 6.598M |
| June 30, 2022 | 8.074M |
| March 31, 2022 | 8.058M |
| December 31, 2021 | 5.856M |
| September 30, 2021 | 6.613M |
| June 30, 2021 | 6.45M |
| March 31, 2021 | 4.899M |
| December 31, 2020 | 6.371M |
| September 30, 2020 | 4.78M |
| June 30, 2020 | 4.681M |
| March 31, 2020 | 2.144M |
| December 31, 2019 | 3.796M |
| September 30, 2019 | 1.503M |
| June 30, 2019 | 1.522M |
| March 31, 2019 | 0.646M |
| December 31, 2018 | 1.192M |
| September 30, 2018 | 1.505M |
| June 30, 2018 | 1.476M |
| March 31, 2018 | 2.298M |
| December 31, 2017 | 1.002M |
| Date | Value |
|---|---|
| September 30, 2017 | 3.503M |
| June 30, 2017 | 3.444M |
| March 31, 2017 | 3.772M |
| December 31, 2016 | 3.433M |
| September 30, 2016 | 3.289M |
| June 30, 2016 | 4.226M |
| March 31, 2016 | 4.377M |
| December 31, 2015 | 2.914M |
| September 30, 2015 | 4.464M |
| June 30, 2015 | 2.60M |
| March 31, 2015 | 3.136M |
| December 31, 2014 | 2.08M |
| September 30, 2014 | 1.979M |
| June 30, 2014 | 1.594M |
| March 31, 2014 | 2.772M |
| December 31, 2013 | 1.395M |
| September 30, 2013 | 1.192M |
| June 30, 2013 | 1.349M |
| March 31, 2013 | 1.752M |
| December 31, 2012 | 1.002M |
| September 30, 2012 | 1.409M |
| June 30, 2012 | 1.215M |
| March 31, 2012 | 0.901M |
| December 31, 2011 | 0.862M |
| September 30, 2011 | 0.655M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
1.503M
Minimum
Sep 2019
9.007M
Maximum
Dec 2022
5.920M
Average
6.45M
Median
Jun 2021
Research and Development Expense (Quarterly) Benchmarks
| Madrigal Pharmaceuticals Inc | 70.64M |
| Viking Therapeutics Inc | 24.10M |
| 89bio Inc | 33.59M |
| Terns Pharmaceuticals Inc | 17.46M |
| Enanta Pharmaceuticals Inc | 36.37M |